NEW DELHI: In what could be good news for patients, Indian Patent Office (IPO) has rejected MNC AbbVie’s patent application for its blockbuster cancer drug Venetoclax citing lack of inventive step.

Indian pharmaceutical companies head into 2026 with a clearer tilt towards specialty medicines as sustained pricing pressure continues to weigh on returns from traditional generics. With export ...

The big medical news of 2026 is about the big blockbuster drug of 2025. Semaglutide (a.k.a. Ozempic, a.k.a. Wegovy) is now off patent in Canada. In the U.S. and the rest of the world, patent ...

Over the past six months, numerous pharmaceutical companies have announced plans to invest in new U.S. manufacturing facilities within the next decade. This so-called “onshoring,” motivated by the ...

Generics of Gilead Sciences' twice-yearly HIV pre-exposure prophylaxis (PrEP) Yeztugo (lenacapavir) are on the horizon, with India's Dr. Reddy’s Laboratories and Hetero Labs striking separate ...

Some Chinese companies now catapulting ahead to make generic versions of Novo Nordisk's Wegovy also provided ingredients for more than a billion makeshift doses of weight-loss drugs sold online in the ...

Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing ...

Community driven content discussing all aspects of software development from DevOps to design patterns. The best way to teach the concept of Java user input to new software developers is to show them ...

“Major” tariffs on pharmaceutical imports are coming soon, President Donald Trump says, pledging that they’d help bring drug manufacturing back to the US while lamenting that other countries pay much ...